Figure 1. A 74-y-old man at initial staging with PSMA PET that demonstrates low uptake in primary tumor (A, arrowhead) and left pelvic side wall node (A, arrow). Bone scan was read as positive by 2 of ...
Extremely low rates of testing of bone mineral density (BMD), as recommended by recent guidelines, were found in a nationwide study of older men receiving androgen deprivation therapy (ADT) for the ...
A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating ...
Use of computed tomography and bone scans in low-risk prostate cancer cases has been in decline, but doctors continue to order these imaging modalities despite professional guidelines that do not ...
The U.S. FDA granted 510(k) clearance to Lantheus Holdings Inc.'s artificial intelligence (AI)-enhanced automated bone scan index (aBSI) product for prostate cancer on GE Healthcare's Xeleris platform ...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI ...
The influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit. Background: The risk of prematurely discontinuing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results